More women with early-stage breast cancer may safely forgo chemotherapy, suggests an interim analysis that had a median follow-up of five years of the large-scale phase-s RxPONDER trial, presented at the San Antonio Breast Cancer Symposium (SABCS) 2020. The investigators reported that adding chemotherapy to endocrine therapy did not improve outcomes for postmenopausal women with … Continue reading Many women could safely skip breast cancer chemo — RxPONDER Trial